Docket Number:14A-990105
Inventor:Pei-Wen Shaw, Chia-Ying Wu, Yi-Chun Yeh
IP Status:US 8980281 B2、TW I494430、US 9795666 B2
Abstract:
Influenza A viruses are major human and animal pathogens with huge economic and societal impact from illness, hospitalizations, and deaths. Virus-like particles (VLPs) of influenza virus have been suggested as a vaccine candidate offering improved safety and efficacy. To develop this concept further, we established a flexible platform to efficiently generate different subtypes of mammalian-expressed influenza VLPs by stable co-expression of four influenza structural proteins (HA, NA, M1, and M2) in a Vero cell line. By replacing the surface glycoproteins of HA and NA, we converted the H3N2-VLP subtype to H5N1-VLP. We further demonstrate that these mammalian VLPs strongly resemble the authentic viruses in structure, particle size and composition of host factors, hemagglutination abilities of secreted VLPs, and even glycosylation of viral antigens. Vaccination of mice with 2.5 μg and above of H5N1-VLP elicited H5-specific IgG1 antibodies and resulted in full protection against lethal infection of homologous virus.
Fields of Application:
Characterization of the mammalian-expressed VLPs demonstrated them as the most advanced mimicry of authentic virus, which permits rapid and scaleable production, independent of a reliance on egg availability for vaccine manufacturing. As a new influenza vaccine, the mammalian VLP fully protected animals from lethal challenge of homologous virus and showed promising functional antibody responses (HI assay), which is the licensure criterion accepted for yearly interpandemic vaccines. Therefore, the VLPs are eligible to be a vaccine candidate against influenza virus, diagnostic reagents, or vaccine antigens to stimulate therapeutic antibodies.
Advantages when compared to the existing technologies:
The VLPs system is the only one based on mammalian expression. Inclusion of the various host cellular proteins, mixed glycosylation types of viral protein and the elicited antibodies of the mammalian-expressed VLPs are all distinct from those of baculovirus-expressed VLPs. Because the mammalian-expressed VLPs are fully recombinant, this can be modified to display other antigens of influenza virus to evade the immune-dominance of HA without concerns over inadequate infection efficiency of recombinant viruses. Therefore, the antigen specificity of mammalian-expressed VLPs is more flexible than the conventional reverse genetic vaccine platform.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
